Emergent BioSolutions secures $200M+ in new smallpox defense contracts globally

Emergent BioSolutions has landed several new contracts to supply smallpox countermeasures. The deals include a $54 million agreement with the US government and additional orders from an unnamed international partner. These moves aim to bolster global biodefence capabilities against potential smallpox threats. The US Administration for Strategic Preparedness and Response (ASPR) awarded Emergent a $54 million contract to deliver CNJ-016, a smallpox treatment. This agreement strengthens national stockpiles as part of ongoing smallpox preparedness efforts.

Separately, an undisclosed international government has placed new orders worth $6.6 million for ACAM2000, a smallpox vaccine. The product will support the country's biodefence strategy, though specific implementation details remain undisclosed.

Emergent has also finalised multi-year agreements with the Government of Canada, valued at up to C$140 million. These contracts focus on enhancing infrastructure for biologic threat preparedness and response. The company continues to expand its role in global health security through these partnerships. The latest contracts add to Emergent's growing portfolio in biodefence. The US and Canadian deals ensure supplies of treatments and vaccines, while the unnamed international partner's order reinforces broader smallpox prevention measures. No further details about the foreign government's specific plans have been made public as of March 2026.